Immunophotonics, Inc. is grateful to NCI (the National Cancer Institute of NIH) and its SBIR Investor Initiatives Team for sponsoring Immunophotonics to present its technology and novel approach to cancer treatment at the BIO CEO & Investor Conference taking place February 6 – 9, 2023 at the New York Marriot Marquis in New York City. ...
Category: Latest News
Immunophotonics Announces 1st Patient Dosed in IP-IIO-622 Phase 1b/2a Clinical Trial in Advanced Solid Tumor Indications
Immunophotonics, Inc. announced the initiation of recruitment and the dosing of its first patient in a clinical trial assessing safety and efficacy of its lead asset, IP-001, in multiple solid tumor indications. This multinational clinical trial, denominated alternately as IP-IIO or INJECTABLE-1, is sponsored by Immunophotonics and will be enrolling patients for treatment of colorectal...
SIO Annual Scientific Meeting, January 19 – 23, 2023
Tomas Hode, PhD, Co-Founder, CIO, and President at @Immunophotonics, Inc. will be attending the Society of Interventional Oncology (SIO) 2023 annual scientific meeting January 19 – 23, in Washington, DC. Tomas will be connecting with interventional oncology professionals from around the world and learning about the latest developments in improving cancer care alongside medical, surgical...
Poster Presented at the ESMO Immuno-Oncology Congress
A poster summarizing the results of the Phase 1b portion of the study SAKK 66/17 concerning the combination of thermal ablation with Immunophotonics’s lead asset, IP-001TM, in patients with advanced solid tumors was presented at the ESMO Immuno-Oncology Congress on December 7-9, 2022, in Geneva, Switzerland. The ESMO Congress is one of Europe’s premier events...
JPM 2023 San Francisco, January 9 – 12, 2023
Our networking is well underway for the JPM 2023. Attending the annual summit Lu Alleruzzo at JPM Healthcare Conference, Theresa Visarius at JPM Biotech Showcase, and Tomas Hode at RESI, in San Francisco January 9 -12, 2023.
Immunophotonics, Inc. was recently named one of six awardees in Johnson & Johnson’s Innovations for Vets: Lung Cancer and Physical Trauma QuickFire Challenge.
We are grateful to Johnson & Johnson Innovation for funding this vital work and are honored to advance medicine for our veterans and military community. This grant will provide Immunophotonics with the opportunity to expand the use of IP-001 into a previously untested combination with chemotherapy as a means of inducing systemic anti-tumor immune responses,...
Florida Venture Summit
Immunophotonics, Inc is proud to have been selected by YoungStartup Ventures to present at the Florida Venture Summit in Miami on December 6th & 7th. Lu Alleruzzo, CEO of Immunophotonics’ will be attending and presenting.
Wei Chen’s Paper Publication in the Journal for ImmunoTherapy of Cancer (JITC)
Congratulations to Professor Wei Chen and his lab at the University of Oklahoma for their publication in one of the top ranked oncology and immunology peer-reviewed journals, the Journal for ImmunoTherapy of Cancer (JITC), on their paper, “Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors”. Check out this key publication on how ablation...
Immunophotonics Co-Founder Wei Chen, Ph.D. Awarded $2.5 Million Grant by the National Cancer Institute
Immunophotonics, Inc. would like to congratulate Wei Chen, Ph.D. on his recently awarded Grant by the National Cancer Institute of Health’s (NIH) National Cancer Institute for pancreatic cancer research. Check out the Official Press Release
RESI Boston 2022 Partnering Platform
Lu Alleruzzo, Co-Founder & CEO, at Immunophotonics, Inc. will be attending the RESI Boston 2022 Partnering Platform, September 21st & 22nd in Boston at the Westin Copley Place.